PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.
Type
Public
HQ
South Plainfield, US
Founded
1998
Size (employees)
320 (est)
Website
ptcbio.com
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, US

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct

PTC Therapeutics Data and Metrics

PTC Therapeutics Financial Metrics

PTC Therapeutics's revenue was reported to be $82.7 m in 2016
Numbers are in $, USD

Revenue (Y, 2016)

82.7 m

Revenue growth (Y, 2015 - Y, 2016), %

125%

Net income (Y, 2016)

(142.1 m)

EBIT (Y, 2016)

(132.1 m)

Market capitalization (25-May-2017)

437.5 m

Closing share price (25-May-2017)

12.6

Cash (31-Dec-2016)

58.3 m
PTC Therapeutics's current market capitalization is $437.5 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015Y, 2016

Revenue

34.7 m25.2 m36.8 m82.7 m

Revenue growth, %

(27%)46%125%

Operating expense total

80.1 m124.7 m203.9 m214.8 m

EBIT

(45.4 m)(99.4 m)(167.1 m)(132.1 m)

EBIT margin, %

(131%)(394%)(455%)(160%)

Interest expense

6.1 m1.2 m

Interest income

1.2 m

Income tax expense

(485 k)(569 k)

Net Income

(66.4 m)(93.8 m)(170.4 m)(142.1 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.4 m49.7 m58 m58.3 m

Accounts Receivable

11.1 m24.9 m

Inventories

1.6 m3.9 m5.9 m4.7 m

Current Assets

145 m323.6 m355.9 m261.3 m

Total Assets

151.9 m333.2 m368 m269.3 m

Accounts Payable

12.2 m29.1 m45.2 m48.8 m

Current Liabilities

13.1 m32.5 m45.4 m49.6 m

Additional Paid-in Capital

465.2 m721.7 m820.2 m856.1 m

Retained Earnings

(328.8 m)(422.6 m)(593 m)(735.1 m)

Total Equity

136.5 m298.5 m226 m119.6 m

Financial Leverage

1.1 x1.1 x1.6 x2.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(51.6 m)(93.8 m)(170.4 m)(142.1 m)

Depreciation and Amortization

2.4 m2.2 m2.9 m3.3 m

Accounts Receivable

(6.9 m)(15 m)

Inventories

(760.5 k)(2.3 m)(2.1 m)1.2 m

Accounts Payable

5.2 m16.9 m17 m4.3 m

Cash From Operating Activities

(46.9 m)(57.3 m)(124.3 m)(103.6 m)

Cash From Investing Activities

(127.8 m)(145.2 m)(20.8 m)104.5 m

Long-term Borrowings

(5 m)(49 k)(49 k)

Cash From Financing Activities

187.4 m237.1 m154.1 m968 k

Interest Paid

367.1 k1 k1 k4.5 m

Income Taxes Paid

2.1 k2 k111 k943 k
Numbers are in $, USDY, 2016

Revenue/Employee

258.5 k

Financial Leverage

2.3 x

PTC Therapeutics Market Value History

PTC Therapeutics Online and Social Media Presence

PTC Therapeutics News and Updates

PTC Therapeutics Company Life and Culture

You may also be interested in